SMI Expanded
1.677,68
PKT
+19,93
PKT
+1,20
%
Werbung
Analysen zu SMI Expanded-Werten
Datum | Rating | Analyst | |
---|---|---|---|
17.02.05 | Zurich Insurance Accumulate | Helvea | |
21.02.05 | UBS Übergewichten | Reuschel & Co | |
17.02.05 | ABB (Asea Brown Boveri) Neutral | Helvea | |
18.02.05 | Zurich Insurance Neutral | Credit Suisse First Boston | |
17.02.05 | UBS Buy | Sarasin Research | |
17.02.05 | Richemont Verkaufen | Helaba Trust | |
17.02.05 | Roche Hold | Crédit Suisse | |
21.02.05 | SGS SA Neutral | Sarasin Research | |
17.02.05 | Lonza Reduce | Sarasin Research | |
18.02.05 | Nestlé In-Line | Goldman Sachs | |
18.02.05 | Lonza Buy | Helvea | |
18.02.05 | Holcim Accumulate | Helvea | |
16.02.05 | Lonza Buy | Helvea | |
16.02.05 | Holcim Halten | Helaba Trust | |
16.02.05 | UBS Kaufen | Hamburger Sparkasse | |
14.02.05 | Nestlé Neutral | Sarasin Research | |
14.02.05 | Holcim Verkaufen | Helaba Trust | |
15.02.05 | UBS Neutral | Merrill Lynch | |
15.02.05 | Swisscom Neutral | Credit Suisse First Boston | |
14.02.05 | Swatch (I) Sector Outperform | Vontobel | |
15.02.05 | Swatch (I) Neutral | JP Morgan | |
11.02.05 | Zurich Insurance Neutral | JP Morgan | |
14.02.05 | UBS Halten | Helaba Trust | |
11.02.05 | Zurich Insurance Outperform | Goldman Sachs | |
14.02.05 | UBS Buy | Sarasin Research | |
21.02.05 | Roche Marketperformer | Sparkasse KölnBonn | |
11.02.05 | Nestlé Neutral | Sarasin Research | |
10.02.05 | Zurich Insurance Buy | Merrill Lynch | |
10.02.05 | UBS Buy | Sarasin Research | |
10.02.05 | Swiss Life Buy | Merck Finck & Co | |
11.02.05 | Swiss Life Akkumulieren | Nord LB | |
10.02.05 | Swiss Life Outperform | HypoVereinsbank | |
10.02.05 | Swiss Life Marketperformer | LB Rheinland-Pfalz | |
10.02.05 | Swiss Life Outperform | HypoVereinsbank | |
10.02.05 | Swiss Life Buy | M.M. Warburg | |
09.02.05 | Roche Buy | Merrill Lynch | |
10.02.05 | Zurich Insurance Halten | Helaba Trust | |
11.02.05 | UBS Outperformer | Sparkasse KölnBonn | |
09.02.05 | Swiss Life Buy | Merck Finck & Co | |
09.02.05 | Novartis Buy | Merrill Lynch |